查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1968602

人工智慧市場分析及2035年臨床試驗預測：按類型、產品、服務、技術、組件、應用、最終用戶及階段分類

AI in Clinical Trials Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Stage
出版日期: | 出版商: Global Insight Services | 英文 336 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計人工智慧在臨床試驗中的應用市場將從2024年的24億美元成長到2034年的111億美元，複合年成長率約為16.5%。該市場涵蓋人工智慧技術的整合，旨在提高臨床研究的效率和準確性。這包括人工智慧驅動的數據分析、最佳化患者招募以及預測建模，以簡化試驗流程。隨著人們對加速藥物研發的需求日益成長，人工智慧在降低成本和改善療效方面的作用變得越來越重要，從而推動了試驗設計和執行方面的創新。

人工智慧在臨床試驗領域的市場正經歷強勁成長，這主要得益於人工智慧技術的日益普及，其能夠提升試驗的效率和準確性。數據管理領域的成長最為顯著，這得益於人工智慧能夠快速處理大量數據，從而實現精準的患者篩選和監測。預測分析工具在這一領域至關重要，它們能夠提高試驗結果預測的準確性，並加快產品上市速度。病患招募和留存領域的成長速度緊隨其後，人工智慧驅動的平台能夠簡化參與者的識別和互動流程，有效解決臨床試驗中最具挑戰性的難題之一。先進的機器學習演算法在此發揮關鍵作用，它們提供個人化的傳播策略，從而提高參與者的依從性。此外，人工智慧在試驗設計最佳化方面的應用也日益普及，它能夠實現自適應試驗設計，從而提高試驗的柔軟性和應對力。人工智慧在這些領域的應用預計將顯著提高效率、降低成本並加速新治療方法的研發，為相關人員帶來盈利的回報。

市場區隔
類型 預測分析、機器學習、自然語言處理、電腦視覺
產品 軟體、平台、工具
服務 資料管理、諮詢、實施支援、支援和維護。
科技 深度學習、神經網路和人工智慧整合系統
成分 硬體、軟體、服務
目的 病患招募、臨床試驗設計、基於風險的監測、藥物發現、數據分析
最終用戶 製藥公司、生技公司、合約研究組織 (CRO)、學術研究機構
階段 臨床前研究、I期臨床試驗、II期臨床試驗、III期臨床試驗、IV期臨床試驗

市場概況：

人工智慧在臨床試驗領域的市佔率正經歷動態變化，老牌企業與新興Start-Ups之間的競爭異常激烈。各公司都在不斷調整定價策略，力求在創新性和可負擔性之間取得平衡。頻繁的新產品發布反映了技術的快速進步以及對提高試驗效率和準確性的追求。這種競爭格局的形成源自於縮短新藥上市時間和改善病患療效的需求。競爭基準研究揭示了激烈的競爭，主要參與者都在研發方面投入大量資金以保持競爭優勢。監管的影響，尤其是在北美和歐洲，至關重要，它們為人工智慧在臨床試驗中的應用設定了嚴格的標準。這些法規確保了安全性和有效性，並對市場動態產生了重大影響。儘管面臨資料隱私問題和對專業人才的需求等挑戰，但創新與合規的整合使該市場具有革新藥物研發流程的潛力。

主要趨勢和促進因素：

由於需要簡化藥物研發流程並降低成本，人工智慧在臨床試驗領域的應用正經歷快速成長。一個關鍵趨勢是將人工智慧演算法整合到患者招募流程中，從而顯著減少識別合適候選受試者所需的時間和資源。這對於加快試驗進度至關重要。另一個趨勢是將人工智慧應用於預測分析，這提高了試驗結果預測的準確性，並有助於改善決策流程。此外，人工智慧驅動的工具正被用於最佳化臨床試驗設計，從而改善資源分配並提高成功率。個人化醫療的興起也推動了人工智慧的應用，因為複雜的數據分析對於個人化治療至關重要。此外，監管機構也日益認知到人工智慧在提高試驗安全性和有效性方面的潛力，並支持其應用。投資於提供擴充性和柔軟性解決方案的人工智慧技術的公司，擁有絕佳的機會來滿足對創新臨床試驗調查方法日益成長的需求。

壓制與挑戰：

人工智慧在臨床試驗領域的應用目前面臨許多重大限制和挑戰。其中一個主要限制是嚴格的法規環境。監管機構要求進行嚴格的檢驗，這增加了時間和成本，並減緩了人工智慧的普及應用。資料隱私問題也是一大挑戰。保護敏感的患者資料至關重要，任何資料外洩都可能導致嚴重的法律後果和信任危機。另一個挑戰是如何將人工智慧整合到現有系統中。許多臨床試驗基礎設施已經過時，需要大量投資才能有效整合人工智慧技術。此外，熟練專家的短缺也是一個問題。業界缺乏既了解人工智慧技術又熟悉臨床試驗複雜性的專家，這阻礙了人工智慧的有效應用。最後，醫學界也存在著一定程度的懷疑態度。一些相關人員仍然對人工智慧的可靠性和準確性持謹慎態度，這減緩了人工智慧在臨床流程中的接受度和整合速度。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 預測分析
    • 機器學習
    • 自然語言處理
    • 電腦視覺
  • 市場規模及預測：依產品分類
    • 軟體
    • 平台
    • 工具
  • 市場規模及預測：依服務分類
    • 資料管理
    • 諮詢
    • 執行
    • 支援和維護
  • 市場規模及預測：依技術分類
    • 深度學習
    • 神經網路
    • 人工智慧整合系統
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
  • 市場規模及預測：依應用領域分類
    • 病患招募
    • 臨床試驗設計
    • 基於風險的監測
    • 藥物發現
    • 數據分析
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 受託研究機構
    • 學術研究機構
  • 市場規模及預測：依階段分類
    • 臨床前階段
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Exscientia
  • BenevolentAI
  • Atomwise
  • Insilico Medicine
  • Owkin
  • PathAI
  • Tempus
  • Recursion Pharmaceuticals
  • CureMetrix
  • BioSymetrics
  • Zebra Medical Vision
  • AiCure
  • Deep Genomics
  • NuMedii
  • BERG

第9章 關於我們

簡介目錄
Product Code: GIS33587

AI in Clinical Trials Market is anticipated to expand from $2.4 billion in 2024 to $11.1 billion by 2034, growing at a CAGR of approximately 16.5%. The AI in Clinical Trials Market encompasses the integration of artificial intelligence technologies to enhance the efficiency and accuracy of clinical research. This market involves AI-driven data analysis, patient recruitment optimization, and predictive modeling to streamline trial processes. As the demand for accelerated drug development rises, AI's role in reducing costs and improving outcomes becomes increasingly pivotal, fostering innovation in trial design and execution.

The AI in Clinical Trials Market is experiencing robust growth, fueled by the increasing adoption of AI technologies to enhance trial efficiency and accuracy. The data management segment is the top performer, driven by AI's ability to process large datasets rapidly, ensuring precise patient selection and monitoring. Within this segment, predictive analytics tools are pivotal, enabling better forecasting of trial outcomes and reducing time to market. The second highest performing segment is patient recruitment and retention, where AI-driven platforms streamline participant identification and engagement, addressing one of the most challenging aspects of clinical trials. Advanced machine learning algorithms are instrumental in this segment, offering personalized communication strategies that improve participant adherence. Additionally, AI applications in trial design optimization are gaining momentum, allowing for adaptive trial designs that enhance flexibility and responsiveness to emerging data. The integration of AI in these areas is expected to drive significant efficiencies, reduce costs, and accelerate the development of new therapies, presenting lucrative opportunities for stakeholders.

Market Segmentation
TypePredictive Analytics, Machine Learning, Natural Language Processing, Computer Vision
ProductSoftware, Platforms, Tools
ServicesData Management, Consulting, Implementation, Support and Maintenance
TechnologyDeep Learning, Neural Networks, AI-Integrated Systems
ComponentHardware, Software, Services
ApplicationPatient Recruitment, Clinical Trial Design, Risk-Based Monitoring, Drug Discovery, Data Analysis
End UserPharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Research Institutes
StagePreclinical, Phase I, Phase II, Phase III, Phase IV

Market Snapshot:

The AI in Clinical Trials market is experiencing dynamic shifts in market share, with established firms and emerging startups competing vigorously. Pricing strategies are evolving as companies aim to balance innovation with affordability. New product launches are frequent, reflecting rapid technological advancements and the quest to enhance trial efficiency and accuracy. This competitive landscape is shaped by the need to reduce time-to-market for new drugs and improve patient outcomes. Competition benchmarking reveals a robust rivalry, with key players investing heavily in R&D to maintain their competitive edge. Regulatory influences, particularly in North America and Europe, are pivotal, as they set stringent standards that guide AI integration in clinical trials. These regulations ensure safety and efficacy, impacting market dynamics significantly. The market is characterized by a blend of innovation and compliance, with AI technologies poised to revolutionize drug development processes, despite challenges such as data privacy concerns and the need for skilled personnel.

Geographical Overview:

The AI in clinical trials market is witnessing rapid growth, with distinct trends across various regions. North America is at the forefront, propelled by substantial investments in AI technologies and a robust healthcare infrastructure. The region's leading pharmaceutical companies are leveraging AI to enhance clinical trial efficiency and accuracy. Europe follows closely, with a strong emphasis on regulatory frameworks and ethical considerations in AI applications. This focus fosters a supportive environment for AI integration in clinical trials. Meanwhile, the Asia Pacific region is emerging as a significant growth pocket, driven by increased investments in healthcare AI and a burgeoning pharmaceutical industry. Countries such as China and India are particularly noteworthy, with significant advancements in AI research and development. Latin America and the Middle East & Africa are also gaining momentum. These regions are recognizing the potential of AI in transforming clinical trials, thereby driving investments and fostering innovation in the healthcare sector.

Key Trends and Drivers:

The AI in Clinical Trials Market is experiencing rapid growth, driven by the need for enhanced drug development efficiency and cost reduction. One key trend is the integration of AI algorithms to streamline patient recruitment, significantly reducing the time and resources spent on identifying suitable candidates. This is crucial in accelerating trial timelines. Another trend is the use of AI for predictive analytics, which enables more accurate forecasting of trial outcomes, thereby improving decision-making processes. Additionally, AI-driven tools are being leveraged to optimize clinical trial design, ensuring better allocation of resources and increased likelihood of success. The rise of personalized medicine is further propelling AI adoption, as tailored treatments require sophisticated data analysis. Moreover, regulatory bodies are increasingly supportive of AI applications, recognizing their potential to enhance trial safety and efficacy. Opportunities abound for companies investing in AI technologies that offer scalable, flexible solutions, positioning themselves to capitalize on the growing demand for innovative clinical trial methodologies.

Restraints and Challenges:

The AI in Clinical Trials Market is currently navigating through several significant restraints and challenges. A primary restraint is the stringent regulatory environment. Regulatory bodies demand rigorous validation, which increases time and costs, delaying AI adoption. Data privacy concerns also pose a challenge. Protecting sensitive patient data is paramount, and any breaches could lead to significant legal repercussions and loss of trust. Another challenge is the integration of AI with existing systems. Many clinical trial infrastructures are outdated, requiring substantial investments to incorporate AI technologies effectively. Moreover, there is a scarcity of skilled professionals. The industry lacks sufficient AI experts who understand both the technology and clinical trial intricacies, hindering efficient implementation. Finally, there is a degree of skepticism within the medical community. Some stakeholders remain cautious about AI's reliability and accuracy, which slows down its acceptance and integration into clinical processes.

Key Players:

Exscientia, BenevolentAI, Atomwise, Insilico Medicine, Owkin, PathAI, Tempus, Recursion Pharmaceuticals, CureMetrix, BioSymetrics, Zebra Medical Vision, AiCure, Deep Genomics, NuMedii, BERG

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Predictive Analytics
    • 4.1.2 Machine Learning
    • 4.1.3 Natural Language Processing
    • 4.1.4 Computer Vision
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software
    • 4.2.2 Platforms
    • 4.2.3 Tools
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Data Management
    • 4.3.2 Consulting
    • 4.3.3 Implementation
    • 4.3.4 Support and Maintenance
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Deep Learning
    • 4.4.2 Neural Networks
    • 4.4.3 AI-Integrated Systems
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Patient Recruitment
    • 4.6.2 Clinical Trial Design
    • 4.6.3 Risk-Based Monitoring
    • 4.6.4 Drug Discovery
    • 4.6.5 Data Analysis
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Companies
    • 4.7.3 Contract Research Organizations
    • 4.7.4 Academic Research Institutes
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Phase I
    • 4.8.3 Phase II
    • 4.8.4 Phase III
    • 4.8.5 Phase IV

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Exscientia
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 BenevolentAI
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Atomwise
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Insilico Medicine
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Owkin
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 PathAI
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Tempus
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Recursion Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 CureMetrix
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 BioSymetrics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Zebra Medical Vision
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 AiCure
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Deep Genomics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 NuMedii
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 BERG
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us